Global Oncology Clinical Science Director

Regulatory Toolkit; Boston (MA); On-site; USD 287,000 - 451,000; Full time

Job summary

Takeda in Boston/Cambridge, MA seeks an Executive Medical Director, Oncology Clinical Sciences to oversee the Integrated Disease Area Strategy and Global Development Plan. You will guide cross‑functional teams, review pivotal study documents, and influence go/no-go decisions while ensuring alignment with regulatory standards.

The role requires strong leadership in clinical development across regions, with oversight of trials, strategy, and external collaborations to drive its oncology portfolio

Qualifications

• MD or combined MD/PhD with 10+ years pharma R&D experience.
• Hematology and/or Medical Oncology background preferred.
• NDA/MAA/Submissions experience strongly preferred.
• Experience leading clinical development teams across multiple regions.

Responsibilities

• Provide strategic clinical input on assigned studies and lead global development teams.
• Oversee study physicians and clinical scientists ensuring timely data review and contingency planning.
• Direct Development Strategy, Clinical Development Plan, and Protocol development.
• Lead regional/global development strategies with timing and regulatory considerations.
• Interface with FDA and other regulatory bodies and key opinion leaders.

Skills

Leadership

Strategic thinking

Communication

Cross-functional leadership

Problem solving

Diplomacy

Travel readiness

Education

MD or MD/PhD

Hematology/Medical Oncology background

Tools

NDA/MAA experience

Job description

Takeda in Boston/Cambridge, MA seeks an Executive Medical Director, Oncology Clinical Sciences to oversee the Integrated Disease Area Strategy and Global Development Plan. You will guide cross‑functional teams, review pivotal study documents, and influence go/no-go decisions while ensuring alignment with regulatory standards.

The role requires strong leadership in clinical development across regions, with oversight of trials, strategy, and external collaborations to drive its oncology portfolio